
FDA Bans Emcure Pharma’s India Plant
FDA released news of the ban of Emcure’s Hinjewadi manufacturing plant after it determined the plant did not meet basic quality standards.
FDA
According to Emcure's website, although its NJ plant is "designed and maintained to prevent cross-contamination and meet cGMP requirements," the company has eight other manufacturing locations, all of which are in India. Only five of its facilities, however, are approved by FDA, according to
In February 2015, Sagent Pharmaceuticals
Source: Reuters
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.